Hikal Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/h1hbw168bajcbfo08f9h4dlm.pdf

Key Takeaways


Pharma: The Growth Engine

Hiremath: "The first ones are the hardest to win. I think we're overcoming that hurdle. And now the next ones will be much easier and will ramp up quite rapidly."

Crop Protection: Stabilization Before Growth

Hiremath: "Based on the above strategic initiatives, although we expect muted growth in FY 2026, we expect growth to resume in FY 2027."

Animal Health & Specialty Chemicals: The Next Legs


High-Potency Chemistry: The Next Capability Unlock

Hiremath: "If you look at the new NCEs that are coming out, more than 50% of the new NCEs are now high potent chemistry."

Costs, Capex & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Pharma revenue growth12% to 15% growth, with EBIT margins rising proportionately through operating leverageFY26
Pharma growth consistency12% to 15% growth year-on-yearFY26 and FY27
Crop Protection revenue and marginsFlattishFY26
Crop Protection growth resumptionGrowth to resume, margins return to FY22/FY23 historical levelsFY27
Crop Protection CDMO commercializationAdvanced-stage projects to launchFY27 onwards
Specialty Chemicals launchesPortfolio to begin launchingH2 FY26
Pharma CDMO commercial scaleTwo NCE programs transition to commercial scale2026-27
High-potency chemistry labCommissioned and operationalQ3 FY26 (operational by end FY26)
Animal Health commercial launchesProduct registration and commercial launches across key global marketsNext several quarters
Food ingredient project peak revenuePeak revenue achievedWithin 2 to 3 years
Capex~₹200 crores each yearFY26 and FY27
Peak PAT recoveryReturn to ~₹160 crores PATAt least 2 to 3 years

Key Metrics

MetricQ4 FY25
Revenue₹552 cr, full year FY25 ₹1,860 cr
EBITDA₹123 cr, +71% QoQ and +31% YoY
EBITDA margin22.4%, improved 410 bps YoY
Full-year EBITDA margin17.7%, improved 270 bps YoY
Pharma revenue₹351 cr, full year FY25 ₹1,168 cr
Pharma EBIT₹55 cr, full year FY25 ₹137 cr, +47% YoY
Pharma EBIT margin improvement327 bps YoY
Crop Protection revenue₹201 cr, full year FY25 ₹692 cr
Crop Protection EBIT₹36 cr, full year FY25 ₹79 cr
Crop Protection EBIT margin18%, full year FY25 11.4%
Total dividend FY25₹1.40 per share, 70% of face value
Pharma revenue growth guidance FY2612% to 15%
Crop Protection growth outlook FY26Flattish revenue and margins; growth expected to resume in FY27
Capex plan FY26 and FY27~₹200 cr each year
ROE FY257.3%
ROCE FY259.9%
PAT FY25₹91 cr, peak PAT was ~₹160 cr in FY22
R&D allocation4% to 5% of revenue consistently
Pharma CDMO pipeline12 to 15 products in advanced stages of development or commercialization, up from 6 to 9 previously
Crop Protection CDMO active projects8 active projects
Animal Health products validated8 products validated under long-term agreement with innovator
Minimum project size target$5 million, ideally $10 million; peak revenue per molecule target ₹50 cr to ₹200 cr+
Agrochemical molecule launch success rateMore than 75%